Skip to main content
. Author manuscript; available in PMC: 2020 Sep 17.
Published in final edited form as: Thromb Res. 2015 Aug 28;136(5):865–869. doi: 10.1016/j.thromres.2015.08.010

Table 3.

Subdistribution hazard ratio for A/A compared to A/T and T/T at rs3809865 (adjusted for either sex, age, stage, metastatic sites, tumor location, BMI or bevacizumab containing treatment).

Factors HR 95% CI P
Parameters analyzed
Unadjusted   7.87 2.31–40.00 0.0005
Adj. for sex   7.52 2.20–38.46 0.0008
Adj. for age   7.63 2.23–40.00 0.0007
Adj. for stage *1 13.89 3.56–76.92 <.0001
Adj. for metastatic sites 12.08 3.42–66.67 <.0001
Adj. for tumor location*2   7.7 2.26–40 0.0006
Adj. for BMI   8.62 2.52–45.45 0.0003
Adj. for bevacizumab*3   8.20 2.31–41.67 0.0006
*1

Stage was determined at CATS admission date. Stage was categorized in stage 1–3 and 4, 3 patients (stage 0) were excluded from analysis.

*2

Three patients with two-sided tumor location were excluded from analysis.

*3

Study patients with unsure treatment of bevacizumab were excluded from the analysis.